D. E. Shaw & Co., Inc. Crispr Therapeutics Ag Transaction History
D. E. Shaw & Co., Inc.
- $100 Billion
- Q1 2025
A detailed history of D. E. Shaw & Co., Inc. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 51,400 shares of CRSP stock, worth $1.87 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
51,400
Previous 74,900
31.38%
Holding current value
$1.87 Million
Previous $2.95 Million
40.67%
% of portfolio
0.0%
Previous 0.0%
Shares
23 transactions
Others Institutions Holding CRSP
# of Institutions
479Shares Held
64.2MCall Options Held
2.15MPut Options Held
1.92M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl10.2MShares$369 Million3.73% of portfolio
-
Capital International Investors Los Angeles, CA6.07MShares$220 Million0.04% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.8MShares$138 Million0.09% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$101 Million0.0% of portfolio
-
Nikko Asset Management Americas, Inc.2.54MShares$92.2 Million1.16% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $2.83B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....